SCIOTEQ
15.2.2024 12:01:28 CET | Business Wire | Press release
ScioTeq, a leading provider of mission-critical defense and avionics visualization and computing solutions, announces the establishment in Bangalore, India of ScioTeq Pvt Ltd, a wholly owned subsidiary of ScioTeq bv. This move will further extend ScioTeq’s global presence by providing Sales, Procurement and Services at its Bangalore location. Additionally, by joining with local partners it will position ScioTeq to support local trade sales and manufacturing of its products and solutions for the Defense market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215830655/en/
ScioTeq Group Worldwide Locations. (Photo: Business Wire)
This move aligns with the “Make in India” initiative of the Government of India to create and encourage companies to develop, manufacture and assemble products made in India and incentivize dedicated investments into manufacturing. The policy creates a conducive environment for business investment, while building a modern structure and opening new sectors for capital investment. It also creates additional jobs that align with the government’s mantra “Atmanirbhar Bharat” (Self Reliant India) which is focused on promoting indigenization in the Defense sector.
“ScioTeq is excited to evolve our long-term relationship with India’s defense community to the next level with this newly established subsidiary,” said ScioTeq Vice President of Defense & Security, Klaas Peerlinck. “It confirms our commitment as a partner in India’s defense manufacturing establishment as well as providing a base to provide dedicated service and sales needs.”
India’s Defense budget is the fourth largest in the world thus providing various opportunities for Defense industries to engage and partner with them as they develop and upgrade their military capabilities. ScioTeq, the largest independent advanced visualization company globally, has engaged with the Indian defense establishment for over two decades, providing critical visualization solutions. This long-term experience in the country, robust portfolio of visualization and computing displays and now a local base of operations, amply positions ScioTeq for future growth and provides the Indian Defense sector with visualization and computing solutions across all three of its services - the Navy, Army, and Air Force.
“We welcome the move by ScioTeq in incorporating a wholly owned subsidiary in India to drive indigenous manufacturing of their products. We value our association and look forward to working with them,” said Mr. Arun Ramchandani, Head of Larsen & Toubro Defence (L&T). L&T is a multinational Indian conglomerate engaged in various industry sectors including defense.
About ScioTeq
ScioTeq has 35+ years’ experience designing, engineering and manufacturing high-tech, innovative, life- and mission-critical computing & visualization solutions for the Air Traffic Control, Avionics and Defense & Security markets. With headquarters in Belgium and five additional locations worldwide, they are a trusted partner in advanced computing & visualization solutions. ScioTeq products are used in the air, on the ground and at sea, delivering mission-critical information to operators on some of the most advanced platforms on the planet and in some of the most challenging environments.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215830655/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release
Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release
Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release
Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom